Gossamer Bio (GOSS) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kalaris Therapeutics (KLRS) has outperformed Gossamer Bio (GOSS) over the past year, losing 62.1% versus a loss of 94.9%. Over five years, GOSS leads with a -99.1% price change compared with -99.5% for KLRS. Gossamer Bio is the larger company by market cap ($60.4 million vs $59.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | KLRS |
|---|---|---|
| Share price | $9.88 | $2.50 |
| Market cap | $60.43M | $59.51M |
| 1-day change | -2.95% | -2.34% |
| YTD return | -96.02% | -70.38% |
| 1-year return | -94.90% | -62.06% |
| 5-year return | -99.12% | -99.51% |
| EPS (TTM) | $-52.80 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $309.60 | $11.88 |
| 52-week low | $9.12 | $2.35 |
| Distance from 52-week high | -96.81% | -78.96% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +734.82% | +648.40% |
| Average volume | 377.00K | 252.88K |
| Shares outstanding | 6.12M | 23.80M |
| Employees | 161 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KLRS has outperformed GOSS by 32.8 percentage points over the past year.
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Healthcare · Biotechnology · 161 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Healthcare · Biotechnology · 20 employees
GOSS vs KLRS FAQ
Which is bigger, Gossamer Bio or Kalaris Therapeutics?
Gossamer Bio (GOSS) is larger, with a market capitalization of $60.43M compared with $59.51M for Kalaris Therapeutics (KLRS).
Which stock has performed better over the past year, GOSS or KLRS?
KLRS returned -62.06% over the past 12 months, compared with -94.90% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.